James Peyer, PhD is the Founder and Chief Executive Officer of Cambrian Bio, a clinical-stage drug development company advancing gerotherapeutics that target the biological mechanisms of aging. Under his leadership, Cambrian has progressed a compound into Phase 2 clinical trials. He also founded Apollo Ventures, one of the first venture capital firms dedicated to the longevity field, which manages over $220 million in assets. Dr. Peyer has served on the boards of both public and private biopharmaceutical companies across geroscience and the broader life sciences. His earlier career included management consulting at McKinsey & Company, with a focus on pharmaceutical strategy. He holds a PhD in stem cell biology from UT Southwestern Medical Center, where he was supported by a National Science Foundation Graduate Research Fellowship, and a BA from the University of Chicago.